Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 114,756 shares of Entrada Therapeutics stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $6.93, for a total value of $795,259.08. Following the completion of the transaction, the insider owned 2,848,310 shares of the company’s stock, valued at approximately $19,738,788.30. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Stock Down 0.3%

Shares of NASDAQ TRDA opened at $7.24 on Wednesday. The stock’s 50-day simple moving average is $6.85 and its two-hundred day simple moving average is $9.79. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.45. The firm has a market capitalization of $281.06 million, a P/E ratio of -1.81 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%.The firm had revenue of $0.88 million during the quarter, compared to the consensus estimate of $2.92 million. As a group, research analysts anticipate that Entrada Therapeutics, Inc. will post -4.12 EPS for the current fiscal year.

Key Headlines Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional investors increased their holdings during the second quarter, including Geode Capital Management, Invesco, Prudential Financial, American Century and RhumbLine Advisers. Institutional and hedge-fund ownership stands at approximately 86.39%, providing some support for the stock. Analysts’ consensus price target of $17.50 is also well above TRDA’s recent trading level, though the consensus rating is “Hold.”
• Neutral Sentiment: Entrada’s latest reported quarterly results beat expectations on earnings, with a loss of $0.95 per share versus the expected $1.06 loss. However, revenue was only $0.88 million compared with the $2.92 million consensus estimate, highlighting the company’s early-stage biotechnology profile and continuing operating losses.
• Negative Sentiment: Director Kush Parmar and major shareholder Ventures L.P. 5AM disclosed sales of 114,756 shares at an average price of $6.93, worth approximately $795,259. The filings appear to describe the same transaction through related insider reports, rather than two separate sales. The transaction reduced the holder’s reported ownership by 3.87%, leaving roughly 2.85 million shares. Entrada Therapeutics insider sale article
• Negative Sentiment: The same parties also reported sales of 1,718 shares at an average price of $6.85, valued at approximately $11,768. This reduced ownership by just 0.06%, making it relatively minor compared with the larger sale. Entrada Therapeutics insider selling alert

Institutional Trading of Entrada Therapeutics

Hedge funds have recently bought and sold shares of the company. State of Wyoming raised its stake in shares of Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after acquiring an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after acquiring an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $68,000. Jain Global LLC purchased a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at $69,000. Finally, IHT Wealth Management LLC bought a new position in shares of Entrada Therapeutics during the 2nd quarter valued at $72,000. Institutional investors own 86.39% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research report on Friday, May 8th. Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Guggenheim cut their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.50.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.